Wellington Management Group LLP Acquires 26,709 Shares of Krystal Biotech, Inc. $KRYS

Wellington Management Group LLP lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 261.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,936 shares of the company’s stock after purchasing an additional 26,709 shares during the quarter. Wellington Management Group LLP owned 0.12% of Krystal Biotech worth $13,728,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of KRYS. Handelsbanken Fonder AB lifted its stake in Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after acquiring an additional 39,000 shares during the period. Fisher Asset Management LLC purchased a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $933,000. William Blair Investment Management LLC lifted its position in Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares during the period. Biondo Investment Advisors LLC boosted its holdings in Krystal Biotech by 31.3% in the fourth quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after purchasing an additional 16,245 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Krystal Biotech by 36.6% in the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after purchasing an additional 69,840 shares during the period. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $358.24 on Tuesday. The business’s 50-day simple moving average is $349.42 and its two-hundred day simple moving average is $308.09. Krystal Biotech, Inc. has a 52 week low of $136.73 and a 52 week high of $382.54. The stock has a market cap of $10.60 billion, a PE ratio of 44.89 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The firm had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KRYS has been the topic of several research analyst reports. TD Cowen increased their price target on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Royal Bank Of Canada assumed coverage on Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price objective for the company. Bank of America upped their price objective on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Citigroup raised their target price on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $365.40.

Insider Buying and Selling

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP John Thomas sold 1,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 51,000 shares of company stock valued at $17,558,270. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.